News

Aroplatin is a liposomal formulation of a proprietary platinum chemotherapeutic. The dose-ranging study will evaluate the safety and pharmacokinetic profile of Aroplatin, which has been reformulated to enhance

The study is evaluating Albuferon (albumin-interferon alpha) in combination with ribavirin in patients who are naive to interferon alpha- based treatment regimens. According to Human Genome, Genotype 1

PharmacoDesign will genotype various Korean populations with the aim of understanding genetic variation and personalizing treatment for optimal clinical outcomes. Under the agreement, Illumina will gain access to

The companies were already aware that there was a possibility the drug may cause liver abnormalities and had ended previous phase II studies being conducted in treatment-naive patients,

The team will be responsible for working with industry, academia and other government agencies to increase the manufacture of anti-influenza drug oseltamivir phosphate (tamiflu) and support clinical studies

Under the terms of the agreement, Rigel will receive initial payments totaling $25 million, comprised of a license fee of $10 million and purchase of $15 million of

ParAllele stockholders will receive approximately $120.8 million in the form of approximately 2.29 million shares of Affymetrix common stock and $11.7 million in cash in exchange for all

Preclinical research has indicated that Imprime PGG significantly enhanced the effectiveness of monoclonal antibody therapy to both kill tumors and increase long-term survival rates. Imprime PGG recruits and

On September 22, 2004, Ortho-McNeil filed a complaint in the US District Court alleging that Caraco’s filing of an ANDA seeking approval to market the generic version of